期刊文献+

盐酸阿那格雷胶囊治疗原发性血小板增多症临床研究

Clinical Study of Anagrelide in the Treatment of Essential Thrombocythemia
暂未订购
导出
摘要 目的研究盐酸阿那格雷胶囊治疗原发性血小板增多症(ET)临床效果。方法选取来我院治疗ET的166例,随机分组,各83例,对照组给予羟基脲片治疗,观察组给予盐酸阿那格雷胶囊治疗,两组均治疗3个月,对比两组疗效与不良反应发生情况。结果治疗后,观察组总有效率为74.6%(62/83),对照组为60.2%(50/83),观察组高于对照组,差异有统计学意义(P<0.05);且不良反应发生率差异无统计学意义(P>0.05)。结论应用盐酸阿那格雷胶囊治疗ET,疗效显著,安全性较好。 Objective To study the clinical effect of anagrelide in the treatment of. Essential Thrombocythemia (ET). Methods 166 cases of ET treated in our hospital were selected, random grouping, each of 83 cases, the control group was given hydroxycarbamide tablets treatment, the observation group was treated with anagrelide, two groups were treated for 3 months, compared with two groups of curative effect and adverse reactions. Results After treatment, the total effective rate of the observation group was 74.6% (62/83), the control group was 60.2% (50/83), the observation group was significantly higher than the control group, the difference was statistically significant (P〈0.05), there was no significant difference in the incidence of adverse reactions (P〉0.05). Conclusion Application of anagrelide in the treatment of ET, the curative effect is remarkable, the security is good.
作者 丁辉
出处 《中国继续医学教育》 2016年第26期159-160,共2页 China Continuing Medical Education
关键词 原发性血小板增多症 阿那格雷 疗效 Essential thrombocythemia, Anagrelide, Curative effect
  • 相关文献

参考文献8

二级参考文献87

  • 1刘焕勋,汪鹏程,凌燕,杜新,卓家才.伊马替尼治疗bcr-abl阳性原发性血小板增多症一例并文献复习[J].白血病.淋巴瘤,2008,17(2). 被引量:2
  • 2张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
  • 3Gaver RC, Deeb G, Piltman KA, eL al. Dispositinn of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther, 1981, 29 : 381-386.
  • 4Petrides PE, Gisslinger H, Sterner M, et al. Pharmacokinetics, bioequivalence, tolerabi|ily, and eftcts on platelet counts of two lbrmulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with Ther,2009, 31: 386-398.
  • 5Arellano-Rodrigo E, Alvarez-Larran A,Reverter JC,et al. Platelet turn-over ,coagulation factors, and soluble markers of platelet and endothelialactiv-ation in essential thrombocythemia : relationship with thrombosis oc-currence and JAK2V617F allele burden [ J]. Am J Hcmatol, 2009,84(2):102-108.
  • 6Palandri F,Ottaviani E,Salmi F,et al. JAK2V617F mutation in essentialthrombocythemia: correlation with clinical characteristics, response totherapy and long-term outcome in a cohort of 275 patients [ J]. LeukLymphoma,2009,50(2) :247,253.
  • 7Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferativeneoplasms the 2008 world health organization criteria and point of carediagnostic algorithms [J]. Leukemia ,2008,22(1) :14 -22.
  • 8Sanchez S, Ewton A. Essential thFombocythemia : a review of diagnosticand pathologic features[ J]. Arch Pathol Lab Med,2006,130: 1144.
  • 9Bri JB. Essential thrombocythemia[ J]. Orphanet J Rare Dis,2007,2:3.
  • 10Molitemo AR, Williams DM, Rogers 0,et al. Molecular mimicry in thechronic myeloproliferative disorders : reciprocity between quantitativeJAK2 V617F and Mpl expression[ J]. Blood ,2006,108 :3913 -3915.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部